Novel Drug Delivery Systems (NDDS)

Global Market Trajectory & Analytics

MCP13631

EXECUTIVE ENGAGEMENTS

POOL

9262
Number of executives repeatedly engaged by snail & email outreach

INTERACTIONS

1296
Interactions with Platform & by Email

PARTICIPANTS

278
Unique # Participated

VALIDATIONS

92
Responses Validated*

COMPANIES

238
Responses Validated*
* Login for a full stack data experience

DATE

SEP 2021

TABLES

32

PAGES

492

EDITION

7

PRICE

USD 4950

CODE

MCP13631


COMPETITIVE METRICS

COMPANY

D S N T

% *

Aquestive Therapeutics, Inc.

20Med Therapeutics

2C Tech

4P Therapeutics

Abbott Laboratories, Inc.

AcelRx Pharmaceuticals

Acerus Pharmaceuticals Corporation

Acuitas Therapeutics

Adare Pharma Solutions

Ademtech SA

*Login to Participate & View Data Stacks
View 238 Companies...

SUBMIT
Note: Best viewed in Landscape Mode
  

HIGHLIGHTS & REPORT INDEX

Global Novel Drug Delivery Systems (NDDS) Market to Reach US$28.1 Billion by the Year 2026

NDDS refer to new approaches, technologies, formulation, and systems used for the transportation of a pharmaceutical compound inside the body for safely achieving its desired pharmacological effects. Growth in the global market is set to be primarily driven by the benefits offered by controlled-release drug delivery systems, including reduced treatment cost, lower side effects, and enhanced therapeutic efficacy. The growing adoption of controlled-release drugs as a standard treatment for various diseases, rising awareness and demand for advanced products among physicians, and increasing prescription of controlled-release products are some of the key factors that are likely to bolster the market growth in the near future. Further, presence of several in-vivo biological barriers that impacts the drug`s stability, absorption, and bioavailability are opening lucrative opportunities for the adoption of controlled-release drug delivery systems. The adoption of controlled-release drug delivery systems is also being propelled by the rapidly growing pediatric and geriatric population, owing to high incidence of non-adherence to prescription drugs in these age-groups. Nanotechnology has come to the fore to further enhance the relevance of continuous improvisation and innovation of NDDS, especially for administering active agents. Several terminal diseases such as immunodeficiency diseases and cancers require controlled and targeted therapy with minimum side effects, and for these systems, nanocarrier-based systems deliver a better therapeutic effect at the target site. Currently, the pharmaceutical industry is preparing for widespread adoption of nanoparticles, which represents a crucial element in advanced nanotechnology-enabled delivery systems.

Amid the COVID-19 crisis, the global market for Novel Drug Delivery Systems (NDDS) estimated at US$9 Billion in the year 2020, is projected to reach a revised size of US$28.1 Billion by 2026, growing at a CAGR of 20.8% over the analysis period. Nanoparticles, one of the segments analyzed in the report, is projected to grow at a 20.3% CAGR to reach US$27.2 Billion by the end of the analysis period. After a thorough analysis of the business implications of the pandemic and its induced economic crisis, growth in the Embolization Particles segment is readjusted to a revised 22.9% CAGR for the next 7-year period. This segment currently accounts for a 17.3% share of the global Novel Drug Delivery Systems (NDDS) market. The rising uptake of nanotechnology and its various concepts including nanocarriers in novel drug delivery mechanisms is driving growth in the Nanoparticles segment. The use of nanoparticles in delivering drugs to cancer cells with minimum damage to healthy cells is the most promising application of nanotechnology in drug delivery currently under development.

The U.S. Market is Estimated at $4 Billion in 2021, While China is Forecast to Reach $2.9 Billion by 2026

The Novel Drug Delivery Systems (NDDS) market in the U.S. is estimated at US$4 Billion in the year 2021. The country currently accounts for a 37.8% share in the global market. China, the world`s second largest economy, is forecast to reach an estimated market size of US$2.9 Billion in the year 2026 trailing a CAGR of 25.7% through the analysis period. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 18% and 19.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 19.5% CAGR while Rest of European market (as defined in the study) will reach US$3.7 Billion by the end of the analysis period.

SELECT PLAYERS

Abbott Laboratories; AstraZeneca PLC; Bayer HealthCare Pharmaceuticals; F. Hoffmann-La Roche AG; GlaxoSmithKline PLC; Johnson & Johnson; Merck & Co., Inc.; Novartis International AG; Pfizer, Inc.

SEGMENTS

» Segment (Nanoparticles, Embolization Particles)

GEOGRAPHIES

» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » and Rest of Europe » Asia-Pacific » Rest of World

TABLE OF CONTENTS

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession
2020: A Year of Disruption & Transformation
As the Race between the Virus & Vaccines Intensifies, Where is the World Economy Headed in 2021
EXHIBIT 1: World Economic Growth Projections (Real GDP, Annual % Change) for 2020 through 2022
An Insight into Pandemic Impact on Pharmaceuticals Industry
COVID-19 & Other Factors Shift Focus to Different Drug Delivery Approaches
Novel Drug Delivery Systems Gain Interest Amid the Fight Against COVID-19
Nanomaterial-enabled Novel Drug Delivery Systems Gain Interest in Vaccine Development
Novel Drug Delivery System (NDDS): A Prelude
Versatile Benefits of NDDS Drive Companies to Embrace the Drug Delivery Approach
Patient Compliance: A Key Reason Garnering Interest in NDD
Regulatory Process for Novel Drug Delivery Systems
A Look into Current Areas of Research in Drug Delivery
Market Outlook
Nanotechnology-Enabled Drug Delivery: Primary Challenges
Recent Market Activity
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Nanotechnology Bolsters Demand for NDDS
Prospects Remain Encouraging
Microfluidics Mediated NDDS Set to Make Gains
Nanocarriers Enable Targeted Drug Delivery Systems to Improve Therapeutic Outcomes
Advanced Liposomes Enable Low Soluble Drugs to Achieve Targeted Delivery
List of Marketed Liposome-Based Clinical Products Classified by Therapeutic Areas
Liposomes-based Drug Delivery Systems to touch Diverse Areas of Modern Medicine
Dendrimers as Ideal Drug Delivery Agents
List of Commercially Available Dendrimeric Products by Application Area
High Drug Loading Capacity of PAMAM Dendrimers Bodes Well for Targeted Drug Delivery Systems
Oral Thin Films Enhance NDDS Domain
Nanotechnology-Enabled Drug Delivery Opens New Horizons to Improve Cancer Treatments
Rising Cancer Incidence Drives Focus onto Novel Drug Delivery Mechanisms
EXHIBIT 8: Global Cancer Incidence: Number of New Cancer Cases in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040
EXHIBIT 10: Number of New Cancer Cases and Deaths (in Million) by Region for 2020
EXHIBIT 11: Global Breakdown of Total Number of Cancer Cases by Type: 2020
Novel Drug Delivery System Emerges as a Potential Treatment for Pediatric Brain Tumors
Uptrend in Gene Therapy Market Augurs Well for Market Growth
Exhibit: Global Gene Therapy Market in US$ Million: 2020, 20223 and 2024
Adeno-Associated Virus Vectors: A Leading Platform for Gene Therapy
Application of Nanotechnology-based Drug Delivery Systems for CVD Treatment
EXHIBIT 12: Global Annual Medical Cost of CVD in US$ Billion (2020-2030)
NDD for Antimicrobial Drugs
List of Select Nanotechnology-based Antimicrobial Drugs in Clinical Use
Nanotechnology Opens New Avenues in Antiretroviral Therapy
Demonstrated Activity of Select Nanotechnology-Delivered Antiretroviral Therapies
Novel Drug Delivery System Exhibits Potential to Target HIV Reservoirs
EXHIBIT 11: Global HIV Prevalence Seeks Need for Novel Drug Delivery Systems: Number of People Living with AIDs (in Thousands) by Region for 2020
Novel Drug Delivery Systems for CNS Therapeutics
Novel Drug and a New Delivery Method for Restoring Brain Cells in People Suffering from PD
Nanotechnology Powers Next Wave of Change for Neglected Tropical Diseases’ Treatment
Novel Drug Delivery Systems Hold Edge over Existing Therapies for Diabetic Retinopathy
Exciting Immunology Developments Involving Graphene-based Nanomaterials
Nanotechnology-Based Strategies for siRNA Grows in Popularity
Nanoemulsions Begin to Make a Mark
Inorganic Nanocarriers Facilitate High Payload Capacity and Co-Delivery Platforms for MDR Cancer Therapy
Solid Lipid Nanoparticles Provide Increased Physical Stability in Targeted Drug Delivery
Recent Advancements in Polymeric Drug Delivery Systems
Pulmonary Delivery of Nanoparticle-Based Drugs Receives Increased Interest
Inhalable Liposome Formulations Attract Research Interest in Pulmonary Delivery
SLNs in Pulmonary Delivery of Drugs
Other Nanocarriers in Pulmonary Delivery
Increasing Importance of Gold Nanoparticles in Targeted Drug Administration
Gold Nanoparticles Open New Avenues in Combinatorial Cancer Therapy
Consistent Rise in Healthcare Spending Worldwide to Drive Market Opportunities
EXHIBIT 14: World Healthcare Expenditure (In US$ Trillion) for the Years for 2017, 2019, 2021 and 2023
4. GLOBAL MARKET PERSPECTIVE
World Current & Future Analysis for Novel Drug Delivery Systems (NDDS) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World 7-Year Perspective for Novel Drug Delivery Systems (NDDS) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2021 & 2027
World Current & Future Analysis for Nanoparticles by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World 7-Year Perspective for Nanoparticles by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2021 & 2027
World Current & Future Analysis for Embolization Particles by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World 7-Year Perspective for Embolization Particles by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2021 & 2027
UNITED STATES
USA Current & Future Analysis for Novel Drug Delivery Systems (NDDS) by Segment - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
USA 7-Year Perspective for Novel Drug Delivery Systems (NDDS) by Segment - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2021 & 2027
CANADA
Canada Current & Future Analysis for Novel Drug Delivery Systems (NDDS) by Segment - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Canada 7-Year Perspective for Novel Drug Delivery Systems (NDDS) by Segment - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2021 & 2027
JAPAN
Japan Current & Future Analysis for Novel Drug Delivery Systems (NDDS) by Segment - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Japan 7-Year Perspective for Novel Drug Delivery Systems (NDDS) by Segment - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2021 & 2027
CHINA
China Current & Future Analysis for Novel Drug Delivery Systems (NDDS) by Segment - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
China 7-Year Perspective for Novel Drug Delivery Systems (NDDS) by Segment - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2021 & 2027
EUROPE
Europe Current & Future Analysis for Novel Drug Delivery Systems (NDDS) by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
Europe 7-Year Perspective for Novel Drug Delivery Systems (NDDS) by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2021 & 2027
Europe Current & Future Analysis for Novel Drug Delivery Systems (NDDS) by Segment - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Europe 7-Year Perspective for Novel Drug Delivery Systems (NDDS) by Segment - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2021 & 2027
FRANCE
France Current & Future Analysis for Novel Drug Delivery Systems (NDDS) by Segment - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
France 7-Year Perspective for Novel Drug Delivery Systems (NDDS) by Segment - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2021 & 2027
GERMANY
Germany Current & Future Analysis for Novel Drug Delivery Systems (NDDS) by Segment - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Germany 7-Year Perspective for Novel Drug Delivery Systems (NDDS) by Segment - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2021 & 2027
ITALY
Italy Current & Future Analysis for Novel Drug Delivery Systems (NDDS) by Segment - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Italy 7-Year Perspective for Novel Drug Delivery Systems (NDDS) by Segment - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2021 & 2027
UNITED KINGDOM
UK Current & Future Analysis for Novel Drug Delivery Systems (NDDS) by Segment - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
UK 7-Year Perspective for Novel Drug Delivery Systems (NDDS) by Segment - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2021 & 2027
REST OF EUROPE
Rest of Europe Current & Future Analysis for Novel Drug Delivery Systems (NDDS) by Segment - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Rest of Europe 7-Year Perspective for Novel Drug Delivery Systems (NDDS) by Segment - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2021 & 2027
ASIA-PACIFIC
Asia-Pacific Current & Future Analysis for Novel Drug Delivery Systems (NDDS) by Segment - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Asia-Pacific 7-Year Perspective for Novel Drug Delivery Systems (NDDS) by Segment - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2021 & 2027
REST OF WORLD
Rest of World Current & Future Analysis for Novel Drug Delivery Systems (NDDS) by Segment - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Rest of World 7-Year Perspective for Novel Drug Delivery Systems (NDDS) by Segment - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2021 & 2027
Total Companies Profiled: 238

PREVIEW REPORT

YOUR PRIVACY MATTERS!

Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.

What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com